FYI: The company that invented Ozempic is imploding. Here's the story.

Alright.

The Danish pharmaceutical company that invented Ozempic, made Wegovy a household name, and briefly became Europe's most valuable corporation is having the worst year of its modern history.

And at the exact same time, the Wegovy pill just put up the biggest drug launch numbers in Novo Nordisk's history.

Both things are true. Most coverage picks a lane. We're going to tell you both stories.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: The company that invented Ozempic is having the worst year of its life. Here's why that matters to you.

Here is what has happened to the maker of Ozempic and Wegovy in the last 12 months.

The last number is the one you haven't heard about. While the first three numbers have been all over financial press since August, the fourth one happened quietly in January, in the middle of the crisis. More on that in a minute.

First, the company itself.

Novo Nordisk is not a typical pharmaceutical company. Three structural facts most readers don't know:

1. Novo can't be acquired. Ever.

The company is majority-controlled by the Novo Nordisk Foundation, a philanthropic trust founded in 1926. The Foundation owns non-tradable Class A shares. The public trades Class B shares on the Copenhagen exchange. No matter how low the stock goes, no matter who bids, Novo cannot be bought by Pfizer, Roche, or any other pharma giant. This is why the company can absorb the current collapse without being broken apart or sold off.

2. The Novo Nordisk Foundation is the largest philanthropic foundation in the world.

$156 billion in assets under management. More than twice the size of the Gates Foundation ($75 billion). Funds scientific research, medical education, and public health infrastructure. This is who actually owns Ozempic. Your copay flows to one of the biggest charitable endowments on earth.

3. Denmark's economy is dependent on Novo.

Novo's 2023 Denmark tax bill was $2.3 billion, the largest in the country. Without Novo's growth, Denmark's economy would have stagnated that year. Analysts call this "the Nokia risk," after Finland's reliance on Nokia in the 2000s. When Nokia fell, Finland's economy took real damage. If Novo stumbles badly, Denmark's welfare state, education budget, and green transition spending all take hits.

That's the company. Now, the crisis.

Start with May 2025. CEO Lars Fruergaard Jorgensen, who'd been at Novo for more than 30 years and had led the company through the entire GLP-1 boom, was abruptly pushed out by the Foundation. The official line was "market challenges." The real line was the stock had collapsed and the Foundation wanted a new playbook.

In late July, Novo named Mike Doustdar as the new CEO. Doustdar started at Novo in 1992 as an office clerk in Vienna. 33 years later he's running the company. Classic Danish corporate succession: internal, patient, Novo-flavored.

One month into the job, Doustdar announced a plan to lay off 9,000 employees, about 11% of the global workforce, to save $1.3 billion per year by late 2026.

In October, the chairman Helge Lund stepped down after a boardroom dispute with the Foundation. Seven board members total were ousted. A former Novo CEO, Lars Rebien Sorensen, was tapped to take over as chairman during the restructuring. An Arthascope trader told Fortune, "I can't recall seeing such a large-scale shake-up all at once, especially not at a company the size of Novo Nordisk."

In November, Novo accepted Medicare's Maximum Fair Price negotiations for Ozempic, Rybelsus, and Wegovy. That drops the Medicare price to $245 per month effective January 2027.

In early 2026, cash-pay Wegovy dropped from $1,349 to $349. That's a 74% price cut on one of the most profitable drugs in modern pharma history.

Then in February, Novo warned that 2026 sales and operating profit would decline 5% to 13%. Stock tanked again.

What caused all of this? One company: Eli Lilly.

Here is the fact the corporate coverage buries.

Earlier in 2025, Zepbound (Lilly's GLP-1) overtook Wegovy in weekly US prescriptions for the first time ever.

That's the actual story. Everything else (the layoffs, the CEO change, the board reshuffling, the price cuts) is the consequence. Novo created the GLP-1 weight loss category. Lilly came in second with a better drug on the weight loss metric (~21% body weight loss vs ~15% for Wegovy). Doctors and patients started switching. Novo's first-mover advantage in US obesity evaporated in about 18 months.

Layer on top of that: compounded semaglutide filled the shortage gap during 2023 and 2024, which meant millions of patients got on semaglutide without touching Novo's cash register. The FDA's May 2025 grace period ending slowed the compounders, but many pivoted to "personalized" formulations that Novo is now suing.

And layer on top of that: the core semaglutide patent expires in 2026 in most international markets. After that, generic semaglutide from China, India, and Brazil floods the world outside the US. The patent cliff is the reason Doustdar is moving fast.

Here is the number you should remember from this issue.

170,000 people started the Wegovy pill in its first four weeks on the US market in January 2026.

That is more than double the previous record for any anti-obesity drug launch in US history. The Wegovy pill launch is happening right now, in the middle of Novo's worst news cycle, and almost nobody is covering it because the corporate crisis is louder.

The pill is outperforming the injection in early uptake. It's easier to prescribe, easier to take, priced at $349 cash or $25 with commercial insurance plus manufacturer savings. Amazon is selling it out of kiosks. Weight Watchers is distributing it. The pill is genuinely working as a category-expanding product.

If Doustdar's restructuring holds, and if the pill keeps this growth through Q2 2026, the Novo rebound story writes itself. If Zepbound keeps eating US market share and the pill plateaus, Novo keeps bleeding. The stock (NVO) is trading around 340 DKK, which UBS set as their price target after the collapse. That's your indicator for how this resolves.

Three things Off Label readers should know even though they're not being said clearly anywhere else.

The layoffs are hitting commercial and administrative roles, not manufacturing. Novo is actually EXPANDING production capacity, including a $4.1 billion plant in Clayton, North Carolina. Ozempic and Wegovy supply is stable. If anything, access is getting easier and cheaper as prices drop.

In 2026, generic semaglutide becomes legal to manufacture and sell in most markets outside the US. That means Chinese, Indian, Brazilian, and European generic versions will flood international markets within 12 to 24 months. If you're traveling or have family abroad, this matters. Prices outside the US will collapse dramatically.

The May 2025 compounding grace period ended but many telehealth companies kept selling "personalized" versions. Novo is pursuing litigation. Every case Novo wins removes a lower-cost alternative from the market. If you're on compounded semaglutide through a telehealth platform, your access may change again depending on how these lawsuits go.

Text your doctor this: "I've been on Ozempic/Wegovy for a while. Given the 2026 price cuts Novo just announced and the Medicare MFP changes coming in 2027, is there anything I should know about my refills, copay, or insurance coverage going forward?"

Copy. Paste. Send. This is the conversation worth having as pricing shifts roll through the system.

The Novo Nordisk story is simultaneously Europe's biggest corporate drama of 2026 AND one of the most complicated stories in modern pharma. A few cultural notes:

Denmark is watching nervously. Danish media and Parliament are actively discussing the Nokia risk. The Foundation is running public relations campaigns to reassure Danish citizens. When a country's economy is this dependent on one company, a corporate restructuring is a national event, not just a business story.

The Metsera bidding war. In October 2025, Novo offered $9 billion for Metsera, a clinical-stage US obesity biotech. Pfizer bid against them. The desperation to secure pipeline replacements tells you everything about how urgently Novo needs the next drug after Wegovy. Most pharma companies don't pay $9 billion for pre-revenue biotech. Novo just did.

The morality layer. When you hear "Big Pharma profiting off desperate patients," understand that Novo's profits flow to a nonprofit philanthropic foundation that funds public health research. That's different from shareholder-owned US pharma. Not defending or condemning, just naming the structure.

The compounding crackdown is shaping telehealth. Hims & Hers, Ro, Henry Meds, and every telehealth company that built revenue on compounded semaglutide now has to pivot. Some are switching to tirzepatide. Some are fighting in court. Some are just accepting losses. Watch this space.

Watch this: Novo Nordisk stock (NVO). Trading around 340 DKK after collapsing 56% from the 2024 peak. If Wegovy pill growth holds through Q2 2026 and Doustdar's restructuring lands, NVO becomes one of the biggest pharma rebound stories of the decade. If Zepbound keeps eating US market share and CagriSema disappoints, NVO keeps bleeding. The Metsera acquisition outcome is a short-term tell. Pipeline replacements matter more for Novo right now than for any company in pharma.

Tomorrow: the data tells a different story than the headlines. We're running the numbers on the GLP-1 market share war, Novo vs Lilly, week by week through 2026, with charts. If you want to know who's actually winning this race, not who's making the most noise, open tomorrow's issue.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions. This applies especially to any changes in your prescription, switching medications, or concerns about drug availability.